Qiagen names Jonathan Pratt as next CEO, effective September 1, 2026

Qiagen N.V. announced on August 24, 2026 that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026, succeeding Thierry Bernard¹. Pratt brings more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare.¹

Pratt's most recent role was as CEO of Filtration Group, a filtration and separation science company, where he oversaw its sale to Parker-Hannifin Corporation, which closed in August 2026. Earlier in his career, he held senior roles at Waters Corporation, where he ran the Waters Division, and at Beckman Coulter Life Sciences, described as a Danaher operating company, and he also held leadership posts at Pall Corporation.

Qiagen said Pratt will also be put forward for shareholder approval as a Managing Director at an Extraordinary General Meeting scheduled for the fourth quarter of 2026.¹

Supervisory Board Chairman Stephen H. Rusckowski said "The Supervisory Board unanimously concluded that Jon Pratt is the right leader for QIAGEN's next phase."¹ Pratt said his early focus would be on listening to employees and customers and identifying where the company can sharpen its strategy, according to the release.

Bernard will step down as CEO and Managing Director and will support an orderly transition through the end of the year.¹ Separately, the filing noted that effective September 1, 2026, Bernard stepped down as a member of the QIAGEN N.V. Managing Board.¹

Qiagen said it has reaffirmed its guidance for the third quarter and full year of 2026. The company also said its Supervisory Board, working with outside financial and legal advisors, is continuing to weigh strategic options intended to build value for shareholders and other stakeholders beyond what the standalone business plan would deliver.